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As the world’s population ages, the number of patients with Alzheimer’s disease (AD) is predicted to increase rapidly.The presence
of neurofibrillary tangles (NFTs), composed of hyperphosphorylated tau protein, is one of the neuropathological hallmarks of AD
brain. Since the presence of NFTs is well correlated with neurodegeneration and cognitive decline in AD, imaging of tau using
positron emission tomography (PET) and single-photon emission computed tomography (SPECT) is useful for presymptomatic
diagnosis andmonitoring of the progression ofAD.Therefore, novel PET/SPECTprobes for the imaging of tau have been developed.
More recently, several probes were tested clinically and evaluated for their utility. This paper reviews the current state of research
on the development and evaluation of PET/SPECT probes for the imaging of tau in AD brain.
1. Introduction
Alzheimer’s disease (AD) is the most common form
of irreversible dementia of the elderly. The number of
AD patients was estimated at 26.6 million worldwide
in 2006. As the world’s population ages, the prevalence
of AD is predicted to grow fourfold, to 106.8 million
in 2050 [1, 2]. Senile plaques (SPs), composed of 𝛽-
amyloid (A𝛽) peptides, and neurofibrillary tangles (NFTs),
composed of hyperphosphorylated tau proteins, are two
neuropathological hallmarks of AD brain [3, 4]. However,
there is no simple and definitive diagnostic method to
detect SPs and NFTs in the brain without postmortem
pathological staining of brain tissue. Therefore, the
quantitative evaluation of SPs and NFTs in living brain
by noninvasive techniques such as positron emission
tomography (PET) and single-photon emission computed
tomography (SPECT) could lead to the presymptomatic
detection of AD [5–7]. Much efforts have been discussed
on the development of A𝛽 imaging probes, and some of
them, such as (E)-4-(N-methylamino)-4󸀠-(2-(2-(2-[18F]-flu-




6-ol ([18F]flutemetamol) [13, 14], were approved by the US
Food and Drug Administration (FDA).
Although SPs are often found in the brains of both
AD and healthy controls, NFTs in the hippocampus and
entorhinal cortex are well correlated with neurodegeneration
and cognitive decline [18, 19]. Furthermore, the formation
and deposition of NFTs occur in the early stage of AD.
Therefore, imaging of tau, which is the main constituent
of NFTs, by PET/SPECT is useful for the presymptomatic
diagnosis and monitoring of the progression of AD. 2-(1-
(2-(N-(2-[18F]-Fluoroethyl)-N-methylamino)naphthalene-
6-yl)ethylidene)malononitrile ([18F]FDDNP), which is
the first PET probe to visualize AD pathology, has been
demonstrated to be effective in the measurement of in vivo
brain cortical accumulation of both SPs and NFTs in living
subjects [20–22]. Since this probe has lower binding affinity
and lack of selectivity for tau aggregates, novel probes that
show high selectivity for tau aggregates have been strongly
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Figure 2: 18F-THK5105 PET images from 60 to 80min after
injection in a healthy control subject (72 years old, CDR 0, MMSE
29) and a patient with Alzheimer’s disease (68 years old, CDR 1.0,
MMSE 20). Reproduced from [23] with permission, copyright 2014
Oxford University Press.
desired. In this review, we summarize the current situation
in the development of imaging probes for tau.
2. Quinoline Derivatives for Imaging of Tau
Okamura and coworkers screened >2000 small molecules in
order to develop novel probes for imaging A𝛽 and tau aggre-
gates. In this search, they identified that the quinoline scaffold
selectively binds to tau aggregates (Figure 1).Therefore, some
compounds were tested for the in vivo imaging of tau in brain
[15]. Among them, 2-[(4-methylamino) phenyl]quinoline
(BF-158) showed high affinity for tau aggregates in vitro
and clearly stained NFTs in the hippocampal section of AD
brain. Furthermore, by in vitro autoradiography in AD brain
sections, the distribution pattern of [11C]BF-158 correlated
well with tau immunostaining in the adjacent section. The
authors suggested that these results indicated the binding of
[11C]BF-158 for NFTs in the AD brain. However, 11C is a
positron-emitting isotope with a short 𝑡
1/2
(20min), which
limits its clinical application. Therefore, they attempted to






for the quantitative imaging of tau aggregates in the human
brain [16, 29]. This probe showed selective affinity for tau
aggregates in vitro. By in vitro autoradiography in AD
brain sections, the distribution of [18F]THK-523 did not
conform with those of 2-(4󸀠-[11C]-methylaminophenyl)-
6-hydroxybenzothiazole ([11C]PIB) [30, 31] and 2-(2-[2-
[11C]-dimethylaminothiazol-5-yl]ethenyl)-6-(2-[fluoro]et-
hoxy)benzoxazole ([11C]BF-227) [32], which are A𝛽 imaging
probes. Furthermore, the distribution of [18F]THK-523
in AD brain section closely resembled the findings upon
Gallyas silver staining and tau immunostaining. On the basis
of these results, [18F]THK-523 was tested clinically [33].
However, the pharmacokinetics and binding characteristics
of [18F]THK-523 might not reach the necessary optimal
levels for PET probes.
Therefore, Okamura and coworkers developed 6-[(3-
[18F]-fluoro-2-hydroxy)propoxy]-2-(4-dimethylaminophe-
nyl)quinoline ([18F]THK-5105) and 6-[(3-[18F]-flu-
oro-2-hydroxy)propoxy]-2-(4-methylaminophenyl)quino-
line ([18F]THK-5117) for use as novel tau imaging PET
probes (Figure 1) [17]. By in vitro binding assays, these
compounds displayed higher affinity to tau aggregates than
THK-523. By in vitro autoradiography in AD brain sections,
the distributions of [18F]THK-5105 and [18F]THK-5117
coincided with Gallyas-Braak staining and tau immuno-
staining but not with the distribution of [11C]PIB and A𝛽
immunostaining. In the biodistribution studies in normal
mice, these probes showed higher uptake to mouse brain at
2min after injection than [18F]THK-523. In addition, the
clearance of these derivatives from normal brain was also
higher than that of [18F]THK-523. These results suggest that
[18F]THK-5105 and [18F]THK-5117 are suitable compounds
for clinical application. Therefore, first, [18F]THK-5105
was tested clinically and evaluated in terms of whether it
could selectively bind to tau aggregates in living patients
with AD [23]. The results of this study suggested that
[18F]THK-5105 is useful for the noninvasive evaluation of tau
pathology in humans (Figure 2). In addition, clinical study
of [18F]THK-5117 is also ongoing.
3. Benzoimidazopyrimidine and
Pyridoindole Derivatives for Imaging
of Tau
Zhang and coworkers designed and synthesized a novel class
of compounds, benzo[4, 5]imidazo[1, 2-a]pyrimidines, for
in vivo imaging of tau in brain (Figure 3) [24]. Among




































Figure 4: Chemical structures of benzothiazole derivatives for the imaging of tau [26–28].
numerous compounds, 4-(benzo[4, 5]imidazo[1,2-a]pyr-
imidin-2-yl)-N-(2-(2-(2-fluoroethoxy)ethoxy)ethyl)aniline
(T557) was identified as having good tau binding properties.
However, imaging studies of [18F]T557 in rodents showed
poor brain uptake. Therefore, they developed 2-(4-(2-[18F]-
fluoroethyl)piperidin-1-yl)benzo[4, 5]imidazo[1,2-a]pyrimi-
dine ([18F]T808) as a novel imaging probe for tau. By in vitro
autoradiography in AD brain sections, this probe localized
in the tau-rich sections with considerable selectivity and
specificity. Compared with [18F]T557, [18F]T808 rapidly
crossed the blood brain barrier, followed by rapid clearance,
suggesting little nonspecific binding in mice.
Xia and coworkers developed a novel class of 5H-
pyrido[4,3-b]indoles and evaluated their binding affinity
toward tau and their selectivity over A𝛽 aggregates (Figure 3)
[25]. Through several rounds of lead optimization, 7-
(6-fluoropyridin-3-yl)-5H-pyrido[4,3-b]indole (T807) was
identified as a novel imaging probe for tau. The results of
in vitro autoradiography in AD brain sections suggested
that [18F]T807 bounded to NFTs of human AD brain with
high specificity and weak or no interaction with SPs. In a
biodistribution study in normalmice, [18F]T807 showed high
brain uptake and rapid clearance from brain. In addition,
[18F]T807 was metabolically stable in mice and [18F]T808
underwent slow yet acceptable de[18F]-fluorination. On the
basis of these results, [18F]T807 and [18F]T808 were tested
clinically. These preliminary results suggested that [18F]T807
and [18F]T808 have promise for the in vivo imaging of tau in
AD patients [34, 35].
4. Benzothiazole Derivatives
for Imaging of Tau
Recently, Honson and coworkers screened to determine
the feasibility of distinguishing tau aggregates from A𝛽
aggregates with a library containing 72,455 compounds
[36]. They found that a phenyldiazenyl benzothiazole
(PDB) derivative showed high binding affinity for tau
aggregates with twofold selectivity over A𝛽 aggregates. Based
on these findings, we designed novel radioiodinated
PDB derivatives and evaluated their utility for the
imaging of tau in AD brain (Figure 4) [26]. Among
them, (E)-4-((6-iodobenzo[d]thiazol-2-yl)diazenyl)-N,N-
dimethylaniline (PDB-3) showed high and selective binding
affinity for tau aggregates in vitro. However, [125I]PDB-3
showed poor pharmacokinetics in normal mouse brain.
Therefore, we developed (E)-4-((6-(2-(2-(2-[18F]-fluoro-
ethoxy)ethoxy)ethoxy)benzo[d]thiazol-2-yl)diazenyl)-N,N-
dimethylaniline ([18F]FPPDB), which is a novel probe for
the imaging of tau, to improve the in vivo pharmacokinetics
of PDB-3 (Figure 4) [27]. [18F]FPPDB showed higher initial
brain uptake and faster clearance from brain than [125I]PDB-
3. However, compared with PDB-3, FPPDB displayed less
selectivity between tau and A𝛽 aggregates. In addition, by
in vitro autoradiography in human AD brain sections, the
distribution of [18F]FPPDB corresponded with that of in
vitro immunohistochemical staining against phosphorylated
tau, but it also matched to immunohistochemical staining
against A𝛽. Therefore, further structural optimization based
on PDB scaffold is necessary to develop more useful probes
for the in vivo imaging of tau in AD brains.
More recently, Maruyama and coworkers developed
novel tau imaging probes, phenyl/pyridinyl-butadienyl-
benzothiazole/benzothiazolium derivatives, for the imaging
of tau in AD brain (Figure 4) [28]. Among them, 2-((1E,
3E)-4-(6-(methylamino)pyridin-3-yl)buta-1,3-dienyl)ben-
zo[d]thiazol-6-ol (PBB3) clearly stained tau aggregates in tau
model mouse brain sections and human AD brain sections.
By ex vivo autoradiography, PBB3 selectively labeled the
brain stem and spinal cord of tau model mice harboring
neuronal tau inclusions. These accumulations could be











Figure 5: Accumulation of [11C]PBB3 in the hippocampal formation of AD patients revealed by in vitro autoradiography (a) and in vivo PET
(b). Reproduced from [28] with permission, copyright 2014 Elsevier.
detected with a micro-PET system in vivo. In addition, by
in vitro autoradiography in AD hippocampus, a notable
difference in the distribution between [11C]PBB3 and
[11C]PIB was observed in the tau-rich sections (Figure 5(a)).
Since these results suggested that [11C]PBB3 is a useful
PET probe for the imaging of tau, they conducted an
exploratory clinical PET study for patients with probable AD
and healthy controls (Figure 5(b)). The result of this study
supported the potential utility of [11C]PBB3 for clarifying
correlations between the distribution of tau deposition and
the symptomatic progression of AD.
5. Other Probes for Imaging of Tau
Rojo and coworkers prepared two benzimidazole derivatives,
astemizole and lansoprazole, to evaluate their interactions
with tau aggregates [37]. Since these compounds showed
high and specific affinity with tau aggregates, radiolabeled
astemizole [38] and lansoprazole [39, 40] derivatives were
reported. In particular, [18F]N-methyl lansoprazole is the
lead compound for progression into clinical trials because
this probe showed rapid brain uptake in nonhuman primates,
favorable kinetics, low white matter binding, and selectivity
for binding to tau aggregates over A𝛽 aggregates. In addition,
some compounds were also developed as novel PET and
SPECT probes for the imaging of tau [41–44].
6. Conclusion
In the past decade, novel PET and SPECT probes for the
imaging of tau were developed and evaluated for their utility.
Among them, several compounds including [18F]THK-523,
[18F]THK-5105, [18F]T807, [18F]T808, and [11C]PBB3 were
tested clinically. The results showed their feasibility for
imaging tau aggregates for the diagnosis of AD.Therefore, we
hope that further studies of these probes should lead to novel
methods for presymptomatic diagnosis andmonitoring of the
progression of AD.
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